ArticleEJHaem2026
Rosuvastatin in Combination With Bortezomib Promotes Osteogenesis in Myeloma Bone Disease by Inhibiting the Secretion of CCL3.
Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Myeloma bone disease (MBD) is a devastating complication of multiple myeloma (MM) and a primary cause of disability in affected patients. Its pathogenesis is driven by an imbalance in bone remodeling, largely attributed to the overexpression of C-C motif chemokine ligand 3 (CCL3). While both bortezomib and statins have been reported to inhibit CCL3, their combined effect on promoting osteogenesis in MBD remains unexplored. This study aimed to investigate the therapeutic potential and underlying mechanism of rosuvastatin in combination with bortezomib for MBD. Methods: Bone marrow samples from MBD patients were analyzed to correlate CCL3 levels with bone turnover markers. Human myeloma cell lines (IM9, XG-1) were treated with bortezomib and/or rosuvastatin. Cell viability was assessed by CCK-8 assay, and CCL3 expression was measured by ELISA and Western blot. A NOD/SCID mouse model of MBD was established to evaluate the in vivo effects on tumor growth, CCL3 secretion (by immunohistochemistry), and bone remodeling (by ALP and TRAP double staining). Results: CCL3 levels were significantly elevated in MBD patients and positively correlated with the severity of bone destruction. The combination of bortezomib and rosuvastatin synergistically inhibited CCL3 secretion in vitro and in vivo more effectively than either monotherapy. Consequently, the combination treatment significantly enhanced osteoblast activity, suppressed osteoclast formation, and improved survival in the murine model. Conclusion: The combination of rosuvastatin and bortezomib exerts a synergistic effect by inhibiting CCL3, thereby rebalancing bone remodeling and promoting osteogenesis. This strategy represents a promising novel therapeutic approach for mitigating MBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.